Key Drivers
- Strong Liquidity
- Negative Cash Flow
- External Funding
AIAI Summary
LBRX has effectively de-risked financing with ~$365.6M in cash and runway into Q2 2029, so the investment now hinges almost entirely on whether LB-102 can translate Phase 2 promise into Phase 3 success and justify multi-indication upside—otherwise it remains a long-dated, binary clinical bet.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Negative Cash Flow
- •External Funding
LBRX has exceptionally strong liquidity and minimal debt, but persistent losses, negative cash flow, and reliance on external financing mean the balance sheet is solid while the business remains unprofitable.
Price Behavior
Key Price Behavior Insights:
- •Failed breakout
- •Support lost
- •Weak momentum
LBRX rallied into early May but then reversed sharply, ending near the last month low below $31 and leaving the short-term trend bearish unless it quickly reclaims support.
Reversed from a $32.88 high to a $29.66 close, signaling a sharp short-term breakdown
Sentiment & News
Key News Insights:
- •Phase 3 launch
- •JAMA publication
- •Bipolar expansion
LB Pharmaceuticals advanced LB-102 from mid-stage validation into pivotal and new Phase 2 testing, boosting its schizophrenia and bipolar depression pipeline.
The updates strengthen LB Pharmaceuticals' clinical momentum by broadening LB-102's late-stage development path and increasing its potential market opportunity
Similar Companies in Healthcare
Other companies in the same sector with AI ratings